Anna Yordanova

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Hojjat Ahmadzadehfar, Elisabeth Eppard, Stefan Kürpig et al. · Oncotarget · 2016 · 282 citations · Full text

Urology, Genitourinary Cancer, Medicine +14

Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis

Kambiz Rahbar, Matthias Schmidt, Alexander Heinzel et al. · Journal of Nuclear Medicine · 2016 · 205 citations · Full text

Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617

Hojjat Ahmadzadehfar, Simone Wegen, Anna Yordanova et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 173 citations

Urology, Radiology, Radioligand Therapy +7

PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival

Kambiz Rahbar, Martin Boegemann, Anna Yordanova et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 159 citations

Urology, Genitourinary Cancer, Medicine +10

The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer

Anna Yordanova, Anja Becker, Elisabeth Eppard et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2017 · 126 citations

Urology, Surgical Oncology, Radioligand Therapy +10